Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage TV Malignant melanoma without prior treatment: A phase Lla trial

Clinical Cancer Research

Volumn 15, Issue 6, 2009, Pages 2123-2129

  Davis, Ian D ^a,b,h   Brady, Ben ^c   Kefford, Richard F ^e   Millward, Michael ^f   Cebon, Jonathan ^a,b   Skrumsager, Birte K ^g   Mouritzen, Ulrik ^g   Hansen, Lasse Tengbjerg ^g   Skak, Kresten ^g   Lundsgaard, Dorthe ^g   Frederiksen, Klaus Stensgaard ^g   Kristjansen, Paul E G ^g   McArthur, Grant ^b,d  

^a AUSTIN HEALTH   (Australia)

^b Cancer Trials ^*  (Australia)

^c CABRINI HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g NOVO NORDISK A S   (Denmark)

^h AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; PERFORIN;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER STAGING; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; LUNG METASTASIS; LYMPHOCYTE COUNT; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NATURAL KILLER T CELL; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; FEMALE; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKINS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; RECOMBINANT PROTEINS; T-LYMPHOCYTE SUBSETS;

EID: 63449095686     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2663     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687-701.
3. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
4. Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
5. McDermott DF, Sosman JA, Gonzalez R, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008;26:2178-85.
6. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45.
7. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6:S11-4.
8. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10:6342-6S.
9. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-52.
10. Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008;26:3445-55.
11. Asao H, Okuyama C, Kumaki S, et al. Cutting edge: the common γ-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001;167:1-5.
12. Habib T, Senadheera S, Weinberg K, Kaushansky K. The common γ chain (γc) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 2002;41:8725-31.
13. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408:57-63.
14. Coquet JM, Kyparissoudis K, Pellicci DG, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007;178:2827-34.
15. Chtanova T, Tangye SG, Newton R, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol 2004;173:68-78.
16. Davis lD, Skak K, Smyth MJ, Kristjansen PEG, Miller DM, Sivakumar PV. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res 2007;13:6926-32.
17. Skak K, Kragh M, Hausman D, et. al. Interleukin 21:combination strategies for cancer therapy. Nat Rev Drug Discov 2008;7:231-40.
18. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and Tcell responses. J Leukoc Biol 2002;72:856-63.
19. Suto A, Nakajima H, Hirose K, et al. Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line ε transcription of IL-4-stimulated B cells. Blood 2002;100:4565-73.
20. WursterAL, RodgersVL, SatoskarAR, et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon γ-producing Th1 cells. J Exp Med 2002;196:969-77.
21. Strengell M, Sareneva T, Foster D, Julkunen I, Matikainen S. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol 2002;169:3600-5.
22. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007;448:484-7.
23. Fantini MC, RizzoA, Fina D, et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th 17 cells. Eur J Immunol 2007;37:3155-63.
24. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007;448:480-3.
25. Dunn GP, Bruce AT, lkeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
26. Davis lD, Skrumsager BK, Cebon J, et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 2007;13:3630-6.
27. + T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 2008;57:1439-49.
28. Davis lD, Brady B, Kefford R, et al. Activity of recombinant human interleukin-21 (rlL-21) in patients (pts) with stage IV malignant melanoma (MM) without prior treatment: clinical data from a phase lla study. J Clin Oncol 2008;26:3042.
29. Thompson JA, Curti BD, Redman BG, et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008;26:2034-9.
30. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
31. Cebon J, Gedye C, John T, Davis ID. Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol 2007;5:994-1006.
32. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169-77.
33. van der Vliet HJ, Koon HB, Yue SC, et al. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res 2007;13:2100-8.
34. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82.
35. Witkowska AM. On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm 2005;2005:121-30.
36. + T lymphocytes. J Immunol 2007;178:732-9.
37. Søndergaard H, Frederiksen KS, Thygesen P, et al. Interleukin 21 therapy increases the density of tumor infiltrating CD8(+)T cells and inhibits the growth of syngeneic tumors.Cancer Immunol Immunother 2007;56:1417-28.
38. Castermans K, Tabruyn SP, Zeng R, et al. Angiostatic activity of the anti-tumor cytokine interleukin-21. Blood 2008;112:4940-7.
39. Dodds MG, Frederiksen KS, Skak K, et al. Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins. Cancer Immunol Immunother 2008. Prepublished online, Oct. 17. 2008. doi:10.1007/500262-008-0600-8.
40. Roda JM, Parihar R, Lehman A, Mani A, Tridandapani S, Carson WE III. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 2006;177:120-9.
41. Roda JM, Joshi T, Butchar JP, et al. The activation of natural killer cell effector functions by cetuximabcoated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007;13:6419-28.
42. Gowda A, Roda J, Hussain SR, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chroniclym-phocytic leukemia cells in vitro. Blood 2008; 111:4723-30.
43. Timmerman JM, Byrd JC, Andorsky DJ, et al. Recombinant interleukin-21 plus rituximab: clinical activity in a phase 1, dose-finding trial in relapsed low-grade B cell lymphoma. American Society of Hematology Annual Meeting; Atlanta, GA;2007.
44. Timmerman JM, Byrd JC, Andorsky DJ, et al. Efficacy and safety of recombinant interleukin-21 (rIL-21) and rituximab in relapsed/refractory indolent lymphoma. J Clin Oncol 2008;26:8554.
45. Bhatia S, Curti BD, Gordon MS, et al. Recombinant IL-21 (rIL-21) in combination with sorafenib: preliminary results from a phase I/II study in patients with metastatic renal cell cancer (RCC). Mol Cancer Ther 2007;6:3354-5S.
46. Bhatia S, Curti BD, Gordon MS, et al. Recombinant IL-21 (rIL-21) in combination with sorafenib: interim results from a phase 1/2 study in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008;26:16008.
47. Sivakumar PV, Johnson B, Brasel K, et al. Preclinical evaluation of IL-21 combination therapy with sorafenib and sunitinib in renal cell carcinoma [abstract 266]. EJCSuppl 2006;4:85.
48. Flaig TW, Curti BD, Gordon MS, et al. Recombinant IL-21 in combination with sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): interim results from a phase 2 study [abstract 204]. EJC Suppl 2008;6:64-5.